This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or placebo (phosphate buffered saline). A total of 60 healthy male and female adults 18 through 45 years of age will be randomized to receive vaccine (30) or placebo (30).
This is a phase 1, double blinded, randomized, placebo-controlled study. The study will be conducted at 1 site in Serbia. Sixty (60) healthy male and female adults, 18 to 45 years of age, will be enrolled into the trial. Subjects will be randomized 1:1 to one of two treatment allocations: 30 to vaccine, 30 to placebo. The study will utilize a "randomized block design" to assure a balance of 1:1 vaccine and placebo when all subjects are enrolled. The study will be double blinded, meaning the study subjects, investigators, and the sponsor will be unaware of the treatment allocated to each subject until the clinical trial database is declared final and locked. The study should take about 5 months to complete, with each subject involved for 3 months from the day of injection. The justification for the 3 month follow up, rather than 6 month follow up is that this is an inactivated vaccine that follows very standard manufacturing practices with standard antigens. The safety of inactivated influenza vaccines is well-established. Adding length to the follow up results in delays in future testing of the vaccine for licensure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
60
Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
0.5 mL of phosphate buffered saline
Clinical Center of Serbia
Belgrade, Serbia
Number of Subjects With Immediate Adverse Events
Number of subjects with observed immediate adverse events, including allergic reaction or anaphylaxis, following administration of the study product.
Time frame: 30-minute post-vaccination period.
Number and Percentage of Subjects With Solicited Local Reactogenicity
Number of subjects reporting solicited local reactions (redness, swelling, induration, pain and tenderness) at the injection site post-vaccination with study vaccine or placebo
Time frame: 7-day period (Days 0-6) post-vaccination.
Number and Percentage of Subjects With Solicited Systemic Reactogenicity
Number of subjects reporting solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or Placebo
Time frame: 7-day period (Days 0-6) post-vaccination.
Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events
These data are presented broadly as number per group for the study. Please see AE reporting section for more specific details on AEs.
Time frame: Within 21 days post vaccination
Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)
Time frame: Over the entire study period (Day 90).
Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.
Seroconversion is defined as a serum HAI titer meeting the following criteria: * pre-vaccination titer \<1:10 and a post-vaccination titer ≥ 1:40 or * pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 21. The 3 influenza strains assessed were B/Massachusetts, H1/A/California and H3/A/Texas
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 21
Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine
A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer ≥ 1:40. The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas
Time frame: Day 0 and Day 21 post vaccination
Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens
The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas
Time frame: Pre- (Day 0) and post-vaccination (Day 21)
Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.
The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas
Time frame: Pre- (Day 0) and post-vaccination (Day 21)
Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.
Time frame: Pre- (Day 0) and post-vaccination (Day 21)
Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.
The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas
Time frame: Pre- (Day 0) and post-vaccination (Day 21)